EU MDR Set To Rack Up Costs For Industry, German Medtechs Say
Executive Summary
Prepare for notified body bottlenecks and skyrocketing clinical evaluation costs for medical devices as you comply with the EU Medical Device Regulation (MDR): that's what German medtech industry delegates were told at a legal and regulatory symposium last week.
You may also be interested in...
With EU Notified Body Numbers Tumbling, How Do Manufacturers Ensure Seamless Transition To MDR?
Device manufacturers in the EU are beginning to realize the extra volume of MDR/IVDR-related work that their pivotal market access partners, the notified bodies, will have to take on. With the regulations' three- and five-year transition period clocks ticking down already, manufacturers must make sure that business continuity is guaranteed – but it won't be easy.
More EU Notified Bodies Bite The Dust
The number of notified bodies operating under the EU's current medical device directives continue to decline, and that trend is expected to persist with the new regulations entering into force. Here's a look at country-by-country trends in notified bodies operating under the three current medtech EU directives.
Scandal-ridden PIP implant firm had been on FDA's radar since 2000
The company at the heart of the recent French silicone breast implant furore, Poly Implant Prosthèse (PIP), had given the US FDA cause for concern as far back as 2000 when an agency inspection of the firm's facility in La Seyne-sur-mer revealed manufacturing and quality control issues.